Mankind Pharma Gets DRDO Nod To Manufacture, Sell Covid Drug 2-DG
NDTV
The office of the Drugs Controller General of India on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients.
Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19. 2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories, Mankind Pharma said in a statement. The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added. The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.More Related News